Literature DB >> 35277357

Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.

Meghan E McGarry1, Elizabeth R Gibb1, Gabriela R Oates2, Michael S Schechter3.   

Abstract

The advent of CFTR modulators, a genomic specific medication, revolutionized the treatment of CF for many patients. However, given that these therapeutics were only developed for specific CFTR mutations, not all people with CF have access to such disease-modifying drugs. Racial and ethnic minority groups are less likely to have CFTR mutations that are approved for CFTR modulators. This exclusion has the potential to widen existing health disparities.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CFTR modulators; Cystic fibrosis; Ethnicity; Race

Mesh：

Substances：

Year:  2021        PMID： 35277357      PMCID： PMC9356388          DOI： 10.1016/j.prrv.2021.12.001

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN： 1526-0542            Impact factor:   5.526


  104 in total

Review 1.  Cigarette smoke and CFTR: implications in the pathogenesis of COPD.

Authors:  Andras Rab; Steven M Rowe; S Vamsee Raju; Zsuzsa Bebok; Sadis Matalon; James F Collawn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-08-09       Impact factor: 5.464

2.  VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Authors:  Dominic Keating; Gautham Marigowda; Lucy Burr; Cori Daines; Marcus A Mall; Edward F McKone; Bonnie W Ramsey; Steven M Rowe; Laura A Sass; Elizabeth Tullis; Charlotte M McKee; Samuel M Moskowitz; Sarah Robertson; Jessica Savage; Christopher Simard; Fredrick Van Goor; David Waltz; Fengjuan Xuan; Tim Young; Jennifer L Taylor-Cousar
Journal:  N Engl J Med       Date:  2018-10-18       Impact factor: 91.245

3.  Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study.

Authors:  Jason Rho; Chul Ahn; Ang Gao; Gregory S Sawicki; Ashley Keller; Raksha Jain
Journal:  Am J Respir Crit Care Med       Date:  2018-10-15       Impact factor: 21.405

4.  Cost of precision medicine at a referral center for cystic fibrosis.

Authors:  Fernando Augusto Lima Marson
Journal:  J Bras Pneumol       Date:  2020-03-02       Impact factor: 2.624

5.  Secondhand smoke inhibits both Cl- and K+ conductances in normal human bronchial epithelial cells.

Authors:  Amy N Savitski; Clementina Mesaros; Ian A Blair; Noam A Cohen; James L Kreindler
Journal:  Respir Res       Date:  2009-11-27

6.  Racial and ethnic disparities in prescription coverage and medication use.

Authors:  Becky Briesacher; Rhona Limcangco; Darrell Gaskin
Journal:  Health Care Financ Rev       Date:  2003

7.  Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations.

Authors:  Joseph M Pilewski; Kris De Boeck; Jerry A Nick; Simon Tian; Cynthia DeSouza; Mark Higgins; Richard B Moss
Journal:  Pulm Ther       Date:  2020-09-23

8.  Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C→T or D1152H Residual Function Mutation.

Authors:  Eitan Kerem; Malena Cohen-Cymberknoh; Reuven Tsabari; Michael Wilschanski; Joel Reiter; David Shoseyov; Alex Gileles-Hillel; Thea Pugatsch; Jane C Davies; Christopher Short; Clare Saunders; Cynthia DeSouza; James C Sullivan; Jamie R Doyle; Keval Chandarana; Nils Kinnman
Journal:  Ann Am Thorac Soc       Date:  2021-03

9.  Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.

Authors:  Carsten Schwarz; Sivagurunathan Sutharsan; Ralph Epaud; Ross C Klingsberg; Rainald Fischer; Steven M Rowe; Paul K Audhya; Neil Ahluwalia; Xiaojun You; Thomas J Ferro; Margaret E Duncan; Bote G Bruinsma
Journal:  J Cyst Fibros       Date:  2020-06-23       Impact factor: 5.527
View more
  2 in total

1.  Coming Full Circle: Reflections and Inspirations from a Cystic Fibrosis Patient Scientist Panel.

Authors:  Alexandra Xan C H Nowakowski; Gabriella Ella Balasa; Miriam F Figueira; Francis Tré J LaRosa; James M J Lawlor
Journal:  Inquiry       Date:  2022 Jan-Dec       Impact factor: 2.099

Review 2.  Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review.

Authors:  Shanal Kumar; Michael Pallin; Georgia Soldatos; Helena Teede
Journal:  J Clin Transl Endocrinol       Date:  2022-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.